# Can SS-31 (Elamipretide) inhibit cuproptosis in chronic asthma for tissue repair?

Canonical source: https://retacompare.com/research/can-ss-31-elamipretide-inhibit-cuproptosis-in-chronic-asthma-for-tissue-repair

Peptide Longevity Q&A · 2026-01-13


    Research indicates that SS-31 (Elamipretide) can inhibit cuproptosis in bronchial epithelial cells, which may contribute to airway remodeling in chronic asthma. This suggests potential implications for tissue repair mechanisms associated with age-related conditions.

 What the research shows

The study investigated the role of cuproptosis in bronchial epithelial cells and its contribution to airway remodeling in chronic asthma. Using a mouse model of chronic asthma induced by repetitive ovalbumin (OVA) exposure, researchers measured levels of copper ions (Cu2+) in bronchoalveolar lavage fluid (BALF) and the expression of cuproptosis-related genes (FDX-1, LIAS, and DLAT). The findings demonstrated that cuproptosis was elevated following OVA exposure, leading to increased airway responsiveness, lung inflammation, subepithelial fibrosis, and mucus hypersecretion. Additionally, the study simulated airway remodeling in vitro with the human bronchial epithelial cell line BEAS-2B, which showed similar increases in cuproptosis markers when treated with recombinant human IL-4 (rhIL-4) and TGF-β1. Importantly, the administration of SS-31 (10 ng/mL) prior to these treatments significantly reduced cuproptosis and its associated effects.

 Why it matters for longevity

The findings of this research have implications for understanding how cellular processes like cuproptosis can influence tissue health and repair, particularly in the context of chronic diseases that may be exacerbated by aging. As chronic asthma is a long-term condition that affects quality of life, the ability of SS-31 (Elamipretide) to inhibit cuproptosis suggests a potential therapeutic avenue not only for asthma but also for age-related tissue degeneration. By targeting the underlying mechanisms of cell death and promoting healthier tissue responses, SS-31 could play a role in enhancing tissue regeneration and overall healthspan.

 Key findings at a glance

Cuproptosis is increased in bronchial epithelial cells in chronic asthma models.

SS-31 (Elamipretide) inhibits cuproptosis and associated airway remodeling.

Increased levels of Cu2+ and expression of cuproptosis-related genes were observed.

SS-31 administration prior to inflammatory treatments reduced cuproptosis markers.

Findings suggest a link between cuproptosis and epithelial-mesenchymal transition (EMT) in airway remodeling.

 How SS-31 (Elamipretide) works (background)

SS-31 (Elamipretide) is a mitochondrion-targeted antioxidant that has shown promise in preclinical studies for its ability to protect against oxidative stress and modulate cell death pathways. By targeting the mitochondria, SS-31 may help mitigate the damaging effects of excessive copper levels that lead to cuproptosis, thereby preserving cell function and promoting healthier tissue responses. This mechanism is particularly relevant in the context of chronic diseases where inflammation and cell death contribute to disease progression and tissue remodeling.

 Safety, caveats, and what we don't yet know

While the study provides valuable insights into the role of SS-31 in inhibiting cuproptosis, it is important to note that this research is preclinical and primarily conducted in animal and cell models. There is still a need for clinical trials to evaluate the safety and efficacy of SS-31 in human populations, particularly in those with chronic asthma or age-related conditions. Additionally, the long-term effects of SS-31 and its potential interactions with other therapies remain to be fully understood.

 Bottom line

SS-31 (Elamipretide) has shown potential in inhibiting cuproptosis in bronchial epithelial cells, suggesting it may play a role in tissue repair mechanisms relevant to chronic asthma and potentially other age-related conditions.

 Related questions

 How does SS-31 (Elamipretide) affect mitochondrial function in aging cells?

Research indicates that SS-31 may enhance mitochondrial function by reducing oxidative stress, which is critical for maintaining cellular health as organisms age.

 Can SS-31 (Elamipretide) improve outcomes in age-related diseases?

Preclinical studies suggest that SS-31 may have therapeutic potential in age-related diseases by protecting against mitochondrial dysfunction and cell death, but further research is needed.

 What is the role of cuproptosis in aging?

Cuproptosis, a novel form of cell death linked to copper accumulation, may play a role in age-related tissue degeneration, highlighting the importance of maintaining copper homeostasis.

 Source: PubMed · Sci Rep · published 2026-01-13.

## Sources

- PubMed · Sci Rep: https://pubmed.ncbi.nlm.nih.gov/41530300/